When: Q3 2026 earnings show clean sequential revenue growth (+5% QoQ) with forward EPS revisions stable at $13-14+ range

Then: Validate thesis, maintain position

When: 2027 IRA pricing list inclusion of Skyrizi/Rinvoq/Imbruvica

Then: Reassess to Underweight regardless of technical setup

SELL

• RSI at 64.35 after multi-week rally with prior peak at 67.69, lacking oversold washout at 44.74; trend extended and vulnerable to quiet rollover
• MACD bullish crossover only 7 trading days old (August 18); prior peak at 10.45 accompanied by RSI extremes that subsequently rolled over
• ATR at 6.16; upper Bollinger band ride after 40% advance from April lows increases risk of violent pullback to midline
• Normalized EPS of $10 assumes most optimistic scenario; if $8, P/E becomes 33x with PEG of 4.1 versus aggressive 0.44
• ABBV has $64 billion net debt, negative book equity, $84 billion intangibles; materially different from MRK/JNJ peer comps
• Q2 2026's $2.03 EPS is single noisy quarter; consensus forward EPS at $16.24 more reliable for risk-adjusted pricing
• WCLC data are early-to-mid stage assets (ABBV-1480, telisotuzumab adizutecan, ABBV-706); AbbVie-Stemcentrx Rova-T failure in 2018 wiped out entire oncology platform after positive data
• Skyrizi dosing change timing undefined (pending); negative catalyst could trigger meaningful drawdown given market expectations
• Ken Griffin 547% position increase is weakest signal; 13F reflects months of buying, Citadel may hold longer for reputational reasons, cost basis unknown
• Zero Fed cuts and 8% recession odds support defensive positioning but ABBV already at upper Bollinger band; IRA expansion to Skyrizi/Rinvoq could trigger 5-10% drop regardless of macro
• Opportunity cost calculation incomplete: $15-25 upside vs $25 downside plus $15-20 gap risk; expected value favors defined risk framework over open-ended directional bet
• 50 SMA stop defines when wrong; holding through 50 SMA to 200 SMA at 224 is stubbornness not conviction
• 10% trim captures neither benefit of concentration reduction nor full upside; 25-30% trim with defined re-entry at $240-250 principled sizing

→ vs aggressive: RSI 64.35 not overbought by textbook definition - but static 70 threshold ignores momentum exhaustion after rally; no real oversold washout means every dip gets bought which is exactly when trends quietly roll over

→ vs aggressive: MACD at 3.73 versus 10.45 prior peak implies massive upside remaining - but prior peak accompanied by RSI extremes that rolled over; fresh crossover only 7 trading days old is momentum setup with little margin for error; bullish crossover failure is reliable short-term reversal signal

→ vs aggressive: Bollinger upper band ride in strong trends - but late-stage 40% advance is different from early-to-middle breakout; volatility is mean-reverting and trends break violently from upper band to midline

→ vs aggressive: PEG of 0.44 math artifact but 26.5 forward P/E in line with peers - but normalized EPS of $10 is guess; if $8, P/E is 33x with PEG of 4.1; peer comp ignores $64B net debt, negative book equity, $84B intangibles versus MRK/JNJ; quality-of-earnings adjusted metrics show meaningful premium

→ vs aggressive: Q2 2026 $2.03 EPS as normalization basis - but single quarter noisy due to milestone payments, royalty true-ups, charge timing; consensus forward EPS of $16.24 more conservative; should model range $8-12 and price at lower end

→ vs aggressive: WCLC pipeline optionality justifies valuation - but data days are years from approvals; Rova-T 2018 failure shows positive early data doesn't guarantee success; pipeline optionality priced as if already revenue is aggressive interpretation

→ vs aggressive: Skyrizi dosing change is single biggest near-term swing factor - but timing undefined (pending); could be next month, next quarter, or 2027; holding full position awaiting undated catalyst is asymmetric risk setup

→ vs aggressive: Ken Griffin 547% position increase signals smart money conviction - but 13F reflects months of buying at unknown cost basis; Citadel may have already trimmed; public profile forces longer holding for reputational reasons; copying hedge fund at 52-week high is textbook retail mistake

→ vs aggressive: Macro tailwinds support defensive positioning so hold ABBV - but defensive bid already in price at upper Bollinger band; IRA drug pricing tail risk is known unknown that cuts against ABBV specifically regardless of rates/GDP; could drop 5-10% on next CMS update

→ vs aggressive: $15-25 upside at $290 breakout justifies holding - but ignores $25 downside to $240 range plus $15-20 gap risk; expected value calculation must weight all realistic outcomes, not just bull case

→ vs aggressive: $246 stop is forced exit before trend plays out - but stops define when wrong not market prediction; holding through 50 SMA to 200 SMA at 224 is gambling not conviction

→ vs aggressive: Harmless 10% trim for mandate reasons - but partial trims capture neither full concentration reduction nor full upside; 25-30% trim with defined $240-250 re-engagement is principled sizing

BUY (trimmed) - Sell 10-15% at ~$265, hold core position, add on $268 close above with volume, exit core below 50 SMA at $247 with volume

• Golden cross intact, rising 200 SMA, 50 SMA holding every pullback since April
• RSI at 64 is not overbought
• MACD just crossed bullish with runway to prior peaks
• Consensus forward EPS of $16.24 already bakes in conservative assumption that charges re-emerge
• Current price ~$265, 10 EMA at $257, 50 SMA at $247
• Price 1.3% below upper Bollinger band (noise, not signal)
• Aggressive analyst's $10 normalized EPS is midpoint of $8-$12 range (picking favorable end)
• 25-30% trim assumes pullback to $240-$250 which is below structural support
• Trimmed position gives up $10-$15/share upside vs $20-$25 full hold, but without directional forecast
• Two defined triggers replace forecast: add on $268 close above with volume, exit on $247 close below with volume

→ vs aggressive: Survivorship bias trap — framing 'trend is intact' as 'must hold full size or add' ignores that every trend looks intact until it doesn't. $10 normalized EPS is picking the favorable end of an $8-$12 range without acknowledging it.

→ vs conservative: Treating every extended position as a sell signal is wrong — price 1.3% below upper band is noise in a confirmed multi-month uptrend. Q2 2026 EPS argument is a red herring since consensus already prices in conservative assumptions. SELL recommendation is structurally flawed because $240-$250 re-entry zone is below 10 EMA ($257) and 50 SMA ($247) where dips get bought.